ARTICLE | Clinical News
Toca 511/Toca FC regulatory update
February 24, 2017 2:21 AM UTC
Tocagen said FDA granted breakthrough therapy designation to Toca 511/Toca FC to treat recurrent high grade glioma. The product is a regimen of Toca 511, a retroviral replicating vector that delivers ...
BCIQ Company Profiles